Regeneron's Eylea snags prefilled syringe approval as Novartis rival looms

Regeneron
Regeneron's Eylea scored a nod for a prefilled injector application to treat four retinal conditions. (Regeneron)

Eye med Eylea has been a blockbuster sales force for Regeneron, but Novartis’ challenger brolucizumab is on the horizon. Could a new delivery option give Eylea a leg up?

That's what Regeneron's hoping. The FDA Tuesday approved a new prefilled injector for 2-milligram single doses of Eylea to treat patients with wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy.

The drugmaker touted the new approval as a game-changer for physicians, taking multiple preparation steps out of the original vial dose regimen. Eylea is now the only drug approved to treat four retinal diseases with a single-dose prefilled injector, although Roche's Lucentis has two prefilled injector doses that cover all four of those indications separately. 

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

Regeneron is hoping the newest green light will help it secure its place as the top-performing wet AMD drug on the market as competitors loom.

RELATED: Regeneron's Eylea pads its armor with diabetic retinopathy approval

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.